Syros Pharmaceuticals (NASDAQ: SYRS) reported Q3 EPS of ($0.41), $0.03 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $5.7 million versus the consensus estimate of $4.49 million.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.